MMP-2 serum concentrations predict mortality in hemodialysis patients: a 5-year cohort study

Clin Chim Acta. 2016 Jan 15:452:161-6. doi: 10.1016/j.cca.2015.11.019. Epub 2015 Nov 26.

Abstract

Background: We evaluated the ability of matrix metalloproteinase (MMP)-2, MMP-9, myeloperoxidase, osteopontin and stromal cell-derived factor 1 to predict mortality in hemodialysis (HD) patients.

Methods: One hundred forty HD patients were enrolled and followed from December 2007 until December 2012. At the end of this 5-year period, data were compared between the patients who were alive and those who had died.

Results: The patients who alive were younger (56 vs. 63y), with lower frequency of diabetes mellitus (34.34% vs. 58.53%), higher concentrations of albumin (4.13 vs. 3.91mg/dl) and lower concentrations of MMP-2 (430.76 vs. 521.59ng/ml). Multivariate analysis showed that age (HR=1.03, p=0.02), diabetes mellitus (HR=2.395, p=0.012), albumin (HR=0.475, p=0.047) and MMP-2 (HR=1.003, p=0.005) were independent factors predicting mortality in HD patients. Receiver operating characteristic curve analysis showed that albumin (AUC=0.628, p=0.027) and MMP-2 (AUC=0.643, p=0.004) had a similar ability (p=0.76) to predict survival of HD patients.

Conclusions: Compared with albumin, serum MMP-2 is a non-inferior prognostic marker for predicting the survival of HD patients.

Keywords: Albumin; Hemodialysis; Matrix metalloproteinase; Survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albumins / analysis
  • Biomarkers / blood
  • Cohort Studies
  • Humans
  • Kaplan-Meier Estimate
  • Matrix Metalloproteinase 2 / blood*
  • Middle Aged
  • Multivariate Analysis
  • Predictive Value of Tests
  • ROC Curve
  • Renal Dialysis / mortality*
  • Software

Substances

  • Albumins
  • Biomarkers
  • Matrix Metalloproteinase 2